Clinical use of novel antithrombotic agents in the management of acute coronary syndromes.


Among patients with ST elevation-acute coronary syndrome (ACS) novel thrombolytic agents can be given as a bolus (reteplase, tenecteplase) and their delivery is easier and may shorten the time to treatment, providing the ideal tool in the pre-hospital setting. Reinfarction after thrombolysis occurs in the 3-5% range in all major trials. Reinfarction after… (More)


  • Presentations referencing similar topics